CA3067730C - Procedes de detection de dysglobulinemie plasmocytaire - Google Patents

Procedes de detection de dysglobulinemie plasmocytaire

Info

Publication number
CA3067730C
CA3067730C CA3067730A CA3067730A CA3067730C CA 3067730 C CA3067730 C CA 3067730C CA 3067730 A CA3067730 A CA 3067730A CA 3067730 A CA3067730 A CA 3067730A CA 3067730 C CA3067730 C CA 3067730C
Authority
CA
Canada
Prior art keywords
splice variants
expression level
subject
plasma cell
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3067730A
Other languages
English (en)
Other versions
CA3067730A1 (fr
Inventor
Irvin Mark Modlin
Mark Kidd
Ignat Drozdov
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Priority claimed from PCT/US2018/042712 external-priority patent/WO2019018540A1/fr
Publication of CA3067730A1 publication Critical patent/CA3067730A1/fr
Application granted granted Critical
Publication of CA3067730C publication Critical patent/CA3067730C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des procédés pour détecter une dysglobulinémie plasmocytaire comme un myélome ou une gammapathie monoclonale de signification indéterminée (GMSI), des procédés pour déterminer si une dysglobulinémie plasmocytaire est stable ou évolutive, des procédés pour déterminer un risque de rechute de maladie, et des procédés pour déterminer une réponse d'un sujet atteint d'une dysglobulinémie plasmocytaire à une thérapie.
CA3067730A 2017-07-21 2018-07-18 Procedes de detection de dysglobulinemie plasmocytaire Active CA3067730C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
US62/535,419 2017-07-21
PCT/US2018/042712 WO2019018540A1 (fr) 2017-07-21 2018-07-18 Procédés de détection de dysglobulinémie plasmocytaire

Publications (2)

Publication Number Publication Date
CA3067730A1 CA3067730A1 (fr) 2019-01-24
CA3067730C true CA3067730C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US10889865B2 (en) Thyroid tumors identified
DK2681333T3 (en) EVALUATION OF RESPONSE TO GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASIS (GEP-NENE) THERAPY
AU2013277971B2 (en) Molecular malignancy in melanocytic lesions
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US12366575B2 (en) Chemical compositions and methods of use
CA2403946A1 (fr) Genes exprimes lors de la differenciation de cellules spumeuses
AU2016377391B2 (en) Triage biomarkers and uses therefor
CN1704478A (zh) 评估急性髓性白血病患者的方法
US12399179B2 (en) Chemical compositions and methods of use
WO2007135174A1 (fr) Modèle d'expression génique prédictif pour le cancer colorectal
CN101778954A (zh) Egfr抑制剂治疗的预测性标记物
US20030175761A1 (en) Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma
CA3067730C (fr) Procedes de detection de dysglobulinemie plasmocytaire
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
HK1084696A (en) Prognostic for hematological malignancy